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Abstract: A small series of 5-nitro-2-aminothiazole-based amides containing arylpiperazine-, 
biphenyl- or aryloxyphenyl groups in their core were synthesized and evaluated as 
antitrypanosomatid agents. All tested compounds were active or moderately active against 
Trypanosoma cruzi amastigotes in infected L6 cells and Trypanosoma brucei brucei, four of 
eleven compounds were moderately active against Leishmania donovani axenic parasites while 
none were deemed active against Trypanosoma brucei rhodesiense. For the most 
active/moderately active compounds a moderate selectivity against each parasite was observed. 
There was good correlation between lipophilicity (clogP value) and antileishmanial activity or 
toxicity against L6 cells. Similarly, good correlation existed between clogP values and IC50 values 
against T. cruzi in structurally related subgroups of compounds. Three compounds were more 
potent as antichagasic agents than benznidazole but were not activated by the type I nitrorectusase 
(NTR). 
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1. Introduction 
American trypanosomiasis (Chagas disease), human African trypanosomiasis (HAT or sleeping 
sickness) and leishmaniasis are considered neglected tropical diseases (NTD) and represent a 
severe global health problem [1, 2]. It is estimated that together these three diseases, caused by 
protozoan parasitic infections, affect approximately 20 million people and are responsible for more 
than 110,000 deaths annually [2]. African trypanosomiasis is endemic in many sub-Saharan 
African countries and is caused by Trypanosoma brucei rhodesiense and Trypanosoma brucei 
gambiense. Chagas disease, caused by Trypanosoma cruzi, is endemic in South and Central 
America but is now spreading worldwide, mainly due to human and vector migration [3,4]. 
Leishmaniasis, caused by more than 20 Leishmania species, occurs throughout tropical and sub-
tropical regions and is now spreading worldwide as an HIV co-infection [5].  
Treatment of these NTD is currently based on a series of problematic drugs. Thus, nifurtimox 
(Nfx) and benznidazole (Bnz), the two currently used medications for Chagas disease are 
associated with limited efficacy, severe toxicity and long treatment requirements [6,7]. Similarly, 
drugs used to treat HAT and leishmaniasis are highly toxic (e.g. melarsoprol, antimonials), may 
require i.v. administration (e.g. melarsoprol, suramin, DFMO, antimonials), can cause severe side 
effects, or are of high cost (e.g. DFMO, liposomal amphotericin B, miltefosine and paromomycin) 
[8-10]. Therefore, there is an urgent need for new effective, safe and affordable alternatives.  
Although inhibitors of the fungal sterol 14α-demethylase enzyme (CYP51) and the 
orthologous enzyme T. cruzi CYP51 (TcCYP51) demonstrated promising efficacy against Chagas 
disease in preclinical studies [11-13], data from clinical trials using posaconazole or ravuconazole 
were disappointing [14, 15]. Moreover, recent evidence indicates that nitroheterocyclics might be 
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more efficacious trypanocidal agents than CYP51 inhibitors [16], and combinations of the two 
may offer even a better solution [17].  
We have shown that several chemical classes of 3-nitro-1H-1,2,4-triazole-based compounds 
exhibit excellent antichagasic activity both in vitro and in vivo [18-25]. Furthermore, appreciable 
anti-HAT activity was also observed in vitro with several such analogs [18-25] whereas in vitro 
antileishmanial activity was demonstrated with a sub-class of 3-nitrotriazole- and 2-
nitroimidazole-based aryloxyphenylamides [25]. Nitro-activation by an oxygen-insensitive type I 
nitroreductase (NTR), an enzyme located in the mitochondrion of trypanosomatids and absent 
from most other eukaryotes, is partially responsible for the trypanocidal activity of these and other 
nitroheterocyclic compounds [18, 19, 21-29]. More recently, we have synthesized 3-nitrotriazole-
based rigid amides and carbinols which act as bifunctional agents; they exert their 
antitrypanosomal activity upon activation by type I NTRs and by inhibiting the parasite’s CYP51 
enzyme [23, 25].  Interestingly, 3-nitrotriazole-based compounds are significantly more potent and 
less toxic than their 2-nitroimidazole-based counterparts [18-25, 30]. 
Here we have expanded our research by investigating the role that another nitroheterocyclic 
ring, 5-nitro-2-aminothiazole, plays in antitrypanosomatid activity. Nitrothiazole- and 
nitrobenzothiazole-containing compounds exhibit antiparasitic, antibacterial, antifungal and 
antitubercular activities [31-34]. Therefore, we have synthesized and evaluated in vitro a small 
series of 5-nitro-2-aminothiazole-based compounds bearing moieties that were previously proven 
effective in the trypanocidal activity of 3-nitrotriazole-based agents.  
 
2. Results and Discussion 
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2.1. Chemistry 
The synthesis of 5-nitro-2-aminothiazole-based compounds (Table 1) is straightforward and based 
on well-established chemistry, outlined in Scheme 1.  
 
Scheme 1: Synthesis of compounds on Table 1. 
 
 
The precursor alkylchloride 1 as well as compound 8 were formed by nucleophilic substitution of 
2-chloroacetyl chloride and [1,1'-biphenyl]-4-carbonyl chloride, respectively, by 5-nitro-2-
aminothiazole, in the presence of triethylamine. Amides 2-7 were obtained by nucleophilic 
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substitution of alkylchloride 1 by an appropriate piperazine at room temperature and in the 
presence of triethylamine. Finally, amides 9-12 were prepared by nucleophilic substitution of 
alkylchloride 1 by the potassium salt of an appropriate phenol in DMF, by heating for 3-4 hours at 
60 oC. Efforts were made to improve the yield of amides 9-12 by changing the solvent to anhydrous 
DMSO or CH3CN without any positive results. All final compounds and intermediates were 
characterized by 1H NMR (500 or 400 MHz) and HRMS. 
 
2.2. Biological Evaluation 
2.2.1. Antiparasitic activity and cytotoxicity  
Compounds in Table 1 were screened for antiparasitic activity against three trypanosomatids: T. 
cruzi, T. b. rhodesiense and Leishmania donovani. The concentration of compound that inhibits 
parasite growth by 50 % (IC50) was calculated from dose response curves for each parasite (Table 
1). In addition, compounds were tested for toxicity in L6 rat skeletal myoblasts, used as host cells 
for T. cruzi amastigotes, in order to calculate a selectivity index for each parasite (SI = 
IC50L6/IC50parasite) (Table 1). Antiparasitic activity was evaluated according to the following 
criteria: an IC50 of <4.0 µM, between 4.0-60 µM or >60 µM, designates ‘active’, ‘moderately 
active’ or ‘inactive’ compounds, respectively, against T. cruzi amastigotes; for blood stream form 
(BSF) T. b. rhodesiense, IC50 values of <0.5 µM, between 0.5-6.0 µM or > 6.0 µM identify ‘active’, 
‘moderately active’ or ‘inactive’ compounds, respectively; finally, for L. donovani amastigotes, 
IC50  of <1 µM, between 1.0-6.0 µM or > 6.0 µM, provides ‘active’, ‘moderately active’ or 
‘inactive’ compounds, respectively [35].  
According to the criteria set above, all tested compounds in Table 1 were active or moderately 
active antichagasic agents (green or light green, respectively). Four compounds (6, 9, 10 and 12) 
were moderately active (light green) against L. donovani parasites whereas no compound 
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demonstrated antiparasitic activity against T. b. rhodesiense. Moreover, all compounds showed 
PSA values >100 Å2, which makes them highly unlikely to be capable of penetrating the blood-
brain barrier and demonstrate anti-HAT activity in vivo. 
 
Table 1. In vitro antiparasitic activity, host toxicity and physical properties of 5-nitro-2-amino-
thiazole-based amides.  
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aT.b. rhodesiense, strain STIB 900 trypomastigotes; bT. cruzi, strain Tulahuen C4 amastigotes; c L. 
donovani axenic, strain MHOM-ET-67/L82 amastigotes; dSI is the ratio: IC50 in L6 cells/IC50 in 
each parasite; ecytotoxicity in the host L6 cells. Reference drugs: Melarsoprol (Melars.), 
Benznidazole (Bnz), Miltefosine (Miltef.). The IC50 value of each reference drug is the mean from 
multiple measurements in parallel with the compounds of interest. Active and moderately active 
compounds are colored green and light green, respectively; inactive compounds are colorless. 
PSA: polar surface area. All physical properties were predicted by using the Marvin Calculator 
(www.chemaxon.com). IC50 values are means of 2 to 3 measurements. The SD was < 5%. 
 
Several analogs (3, 5-9) demonstrated IC50 values < 50 µM against L6 host cells, presumably 
due to their high lipophilicity (Table 1), resulting in low selectivity indices. However, even 
compounds with IC50 values > 50 µM against L6 cells demonstrated a less than ideal SI, which is 
desired to be ≥ 50 for T. cruzi and ≥ 20 for L. donovani [35]. 
 
2.2.2. SAR analysis of antichagasic activity 
The compounds in Table 1 were synthesized having in mind 3-nitro-1,2,4-triazole-based analogs 
with known substantial trypanocidal properties, described previously by this group [20, 23-25].  
Taking a closer look at the piperazine derivatives 2-7, we observe that these yielded IC50 values 
against T. cruzi  parasites ranging from 0.571 to 9.31 µM; thus they are 1.1- to 9-fold less potent 
than the corresponding 3-nitrotriazole-based analogs (IC50 values 0.169 to 4.64 µM) [24]. 
Similarly, the aryl/aryloxy-derivatives 8-12 were only moderately active antichagasic agents, 
compared to 3-nitrotriazole-based aryloxyphenylamides which demonstrate T. cruzi IC50 values at 
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low nM concentrations [23, 25]. Therefore, clearly 5-nitro-2-aminothiazole-based amides are less 
potent antichagasic agents than their 3-nitrotriazole-based analogs.  
Another general observation is that the 5-nitro-2-aminothiazole-based amides are significantly 
more lipophilic (Table 1) than their 3-nitrotriazole-based counterparts with the latter having clogP 
values between -0.198 and 3.1. In addition, 5-nitro-2-aminothiazole-based amides demonstrate 
higher PSA values than their 3-nitrotriazole-based analogs (the latter having PSA values less than 
116 [24]), which may negatively affect cell permeation [36]. These features may contribute to the 
higher toxicity of the nitroaminothiazoles in L6 cells and their reduced potency against the 
parasites (Table 1). 
 
 
Fig. 1. Correlation between antichagasic activity (log IC50 values against T. cruzi) and lipophilicity 
(clogP values) in 3-7, compounds that are active against T. cruzi and bear a piperazine moiety. 
 
There was an excellent correlation between antichagasic activity and lipophilicity (R2=0.979) 
in the piperazine-amide subgroup of compounds 3-7 (which were active against T. cruzi) as shown 
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in Fig. 1. Thus, the piperazine amide 6 with the highest clogP value (4.51) was the most active 
compound against T. cruzi, demonstrating an IC50 of 571 nM, 3.86-fold more active than Bnz 
(Table 1). Compound 6, however, was about 8-fold less active than its 3-nitrotriazole-based 
analog, in which the piperazinic ring is directly connected with the carbonyl (piperazide) and the 
nitrotriazole ring is connected with the carbonyl through a methylene group [24]. SAR follows the 
same rules observed in the 3-nitrotriazole-based piperazines and piperazides [20, 24]. Therefore, 
dichlorophenylpiperazine 5 was a slightly better antichagasic agent than 
trifluoromethylphenylpiperazine 3, the latter demonstrating better antichagasic activity than the 
methoxyphenylpiperazine 4 or the heteroarylpiperazine 7. It is not clear if the electronic effect of 
substitution plays a role in activity other than influencing the clogP value. 
 
 
Fig. 2. Correlation between antichagasic activity (log IC50 values against T. cruzi) 
and lipophilicity (clogP values) in the subgroup of structurally similar compounds 8-12. 
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With regard to in the structurally related compounds 8-12, there was also excellent correlation 
between antichagasic activity and lipophilicity (R2 = 0.977), with the most lipophilic 
biphenylamide 8 having the lowest IC50 value against T. cruzi (Fig. 2). Interestingly, and despite 
their relatively high lipophilicity, the (phenoxy/phenyl)phenoxy-derivatives 9-12 were only 
moderately active antichagasic agents, in stark contrast to 3-nitrotriazole-based 
aryloxyphenylamides, which were exceptionally active (at low nM concentrations) against T. cruzi 
[25]. 
 
2.2.3. Analysis of anti-Leishmania activity 
There was no correlation between antichagasic and antileishmanial activity for compounds 2-12. 
Thus, compounds 9, 10 and 12 that displayed a moderate antichagasic activity (IC50 values of 23 
to 35 µM) demonstrated high potency towards L. donovani, yielding IC50s of 4.27 to 5.40 µM.  
 
Fig. 3. Correlation between log IC50 values against L. donovani and clogP values for compounds 
in Table 1. 
In contrast to antichagasic activity and, with the exception of the most lipophilic compound 6, 
the 3-nitro-2-aminothiazole-based piperazine amides 2-7 were generally less active 
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antileishmanial agents than the (phenoxy/phenyl)phenoxy derivatives 9-12. With regard to the role 
of substitution in the antileishmanial activity, the same rules existed, which were mentioned above 
for antichagasic activity. There was good correlation between clogP and logIC50 values against L. 
donovani parasites for all compounds (Table 1), regardless of activity (Fig. 3). Therefore, once 
again, lipophilicity was very important determinant for antileishmanial activity. However, 
lipophilicity also resulted in relatively high toxicity with good correlation between clogP values 
and logIC50 values in L6 cells (Fig. 4). 
 
Fig. 4. Correlation between log IC50 values in L6 cells and clogP values for compounds in Table 
1. 
 
2.2.4. The role of Type I nitroreductases. 
To elucidate the mechanism of action of the novel compounds in Table 1, representative 
derivatives  (3, 5, 6, 7, 8 and 11) were evaluated as substrates of purified, recombinant TbNTR 
and their enzyme specific activity, measured as nmol NADH oxidized min-1 mg-1 protein, 
compared with that of benznidazole (Fig. 5). With the exception of compound 3, all other tested analogs 
13 
 
were deemed to be poor TbNTR substrates, consistent with results obtained for previously studied 
N-substituted 5-nitro-2-aminothiazoles where the substituent had electron withdrawing groups 
[37]. Compound 3, which was not the most potent analog against T. cruzi amastigotes, provided a 
similar TbNTR specific activity to BNZ (Fig. 5).  
 
 
Fig. 5. Specific activity values are measured in nmol NADH oxidized min-1 mg-1 TbNTR. The 
values correspond to averages from assays performed in triplicate ± standard deviation 
 
To further determine whether NTR plays a role in metabolizing the substrates within the 
parasite, the above subset of compounds were phenotypically screened against BSF T. b. brucei 
expressing wild type or elevated levels of TbNTR. Compound 7, with an IC50 >10 µM in wild type 
parasites was not screened against the recombinant line. For most of the remaining compounds 
cells overexpressing TbNTR were only 2- to 3-fold more sensitivity than controls to the agent, a 
relatively low shift when compared to that observed with nifurtimox. The biochemical and 
phenotypic screening data suggest that NTR plays little or no role in the metabolism of these 
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compounds within the parasite itself. As these ‘non-TbNTR’ activated compounds display 
moderate growth inhibitory properties towards wild type T. b. brucei (Table 2) the mode of action 
of these compounds remains unknown although this antitrypanosomal activity does appear to be 
sub-species specific: The selected 5-nitrothiazole-based compounds tested are up to 12-fold more 
potent towards T. b. brucei than against T. b. rhodesiense. 
 
Table 2. Activity of selected nitrothiazoles against wild type and TbNTR overexpressing  
T. b. brucei parasites in the presence of tetracycline (+tet). 
 
 
In conclusion, novel N-substituted 5-nitro-2-aminothiazoles with an arylpiperazine-, biphenyl- 
or aryloxyphenyl group in the core were active or moderately active antichagasic agents and 
moderately active against T. b. brucei parasites. Only one derivative, compound 6, demonstrated 
activity against T. cruzi amastigotes at nM concentrations and was about 4-fold more potent than 
BNZ. In addition, some of these compounds demonstrated a moderate antileishmanial activity 
against L. donovani axenic amastigotes. These particular compounds were not good substrates for 
Ratio
wild type TbNTR (-tet) TbNTR (+tet) –tet/+tet
nfx 6.359 ± 0.119 0.869 ± 0.046 7.3
3 1.019 ± 0.045 1.460 ± 0.113 0.526 ± 0.024 2.8
5 1.365 ± 0.091 1.957 ± 0.101 0.747 ± 0.075 2.6
6 1.474 ± 0.104 1.638 ± 0.069 0.636 ± 0.022 2.6
7 21.575 ± 3.630 - - -
8 1.612 ± 0.396 4.587 ± 0.149 2.176 ± 0.085 2.1
11 3.753 ± 0.383 3.249 ± 0.142 2.200 ± 0.100 1.5
compound IC50 value (µM) T.b. brucei
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type I NTR. However, more simple N-substituted 5-nitro-2-aminothiazoles were shown to be 
excellent substrates of type I NTR and their antiparasitic activity was increased about 10-fold in 
NTR overexpressing T. b. brucei [37]. Interestingly, these more simple N-acyl substituted 5-nitro-
2-aminothiazoles demonstrated significantly lower clogP values than the compounds described in 
here [37]. Therefore, this class of compounds deserves further investigation and structural 
optimization may provide leads for further development. 
 
3. Experimental 
3.1. Chemistry 
3.1.1. General 
All starting materials and solvents were purchased from Sigma-Aldrich (Milwaukee, WI), were of 
research-grade quality and used without further purification. Solvents used were anhydrous and 
the reactions were carried out under a nitrogen atmosphere and exclusion of moisture.  Melting 
points were determined by using a Mel-Temp II Laboratory Devices apparatus (Holliston, MA) 
and are uncorrected. Proton NMR spectra were obtained on a Varian Inova-500 or an Agilent Hg-
400 spectrometer at 500 or 400 MHz, respectively, and are referenced to Me4Si or to the 
corresponding solvent, if the solvent was not CDCl3. High-resolution electrospray ionization 
(HRESIMS) mass spectra were obtained on a Agilent 6210 LC-TOF mass spectrometer at 11000 
resolution.  Thin-layer chromatography was carried out on aluminum oxide N/UV254 or polygram 
silica gel G/UV254 coated plates (0.2 mm, Analtech, Newark, DE). Chromatography was carried 
out on preparative TLC alumina GF (1000 microns) or silica gel GF (1500 microns) plates 
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(Analtech). All final compounds were purified by preparative TLC chromatography on silica gel 
or alumina plates and also checked by HPLC (≥ 95% purity).   
 
3.1.2. Synthesis of 2-chloro-N-(5-nitrothiazol-2-yl)acetamide (1)[33]: 
A suspension of 5-nitrothiazol-2-amine (1 eq) and triethylamine (1.1 eq) in 10 mL 
dichloromethane  was added drop wise to a dichloromethane solution (5-7 mL) of 2-chloroacetyl 
chloride (1.1 eq)  and the reaction was left overnight at room temperature. Alternatively, the 
solution of 2-chloroacetyl chloride was added at once to the suspension of 5-nitrothiazol-2-amine 
and triethylamine. The TLC on silica gel with ethyl acetate: petroleum ether (75:25) indicated 
completion of the reaction. The desired product was isolated as light yellow crystals through 
column chromatography as above: 481 mg (81% yield).  
 
3.1.3. General synthesis of N-(5-nitrothiazol-2-yl)acetamides 2-7: 
A dichloromethane solution (6 mL) of an appropriate piperazine (1 eq) and triethylamine (3 eq) was added 
drop wise to a suspension of 2-chloro-N-(5-nitrothiazol-2-yl)acetamide  (1) in 5 mL CH2Cl2 and the reaction 
was kept at room temperature under a nitrogen atmosphere and stirring for 48 h. The reaction solvent was 
evaporated and the residue was redissolved in ethyl acetate. The inorganic salts were filtered away and the 
residue was chromatographed on preparative TLC silica gel plates with ethyl acetate/petroleum ether as 
eluent to obtain the desired pure product as a powder or crystals. Purity was also checked by HPLC and it 
was ≥ 95%.   
 
3.1.3.1. N-(5-nitrothiazol-2-yl)-2-(4-(p-tolyl)piperazin-1-yl)acetamide (2): Orange microcrystallic 
powder (62%): mp 160-161 oC (dec); 1H NMR (400 MHz, (CDCl3) δ: 8.33 (s, 1H), 7.10  (d, J = 7.6 Hz, 
2H), 6.85 (d, J = 8.8 Hz, 2H), 3.38 (s, 2H), 3.23 (t, J = 4.8 Hz, 4H), 2.81 (t, J = 5.2 Hz, 4H), 2.29 (s, 3H).  
HRESIMS calcd for C16H20N5O3S m/z [M+H]+  362.1281 found 362.1285.  
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3.1.3.2. N-(5-nitrothiazol-2-yl)-2-(4-(4-(trifluoromethyl)phenyl)piperazin-1-yl)acetamide (3): 
Orange powder (55%): mp 173-175oC; 1H NMR (400 MHz, (CDCl3) δ: 8.33 (s, 1H), 7.51 (d, J = 8.4 Hz, 
2H), 6.96 (d, J = 8.4 Hz, 2H), 3.40 (s, 2H), 3.38 (t, J = 5.2 Hz, 4H), 2.82 (t, J = 5.2 Hz, 4H). HRESIMS 
calcd for C16H16N8O4S m/z [M+H]+ 416.1010, found 416.1005. 
 
3.1.3.3. 2-(4-(4-methoxyphenyl)piperazin-1-yl)-N-(5-nitrothiazol-2-yl)acetamide (4): Bright orange 
powder (57%): mp 154-156 oC (dec); 1H NMR (400 MHz, (CDCl3) δ: 8.33 (s, 1H), 6.91 (d, J = 8.8 Hz, 
2H), 6.86 (d, J = 9.2 Hz, 2H), 3.78 (s, 3H), 3.39 (s, 2H), 3.17 (t, J = 4.8 Hz, 4H), 2.81 (t, J = 4.8 Hz, 4H). 
HRESIMS calcd for C16H20N5O4S m/z [M+H]
+  378.1231 found 378.1233. 
 
3.1.3.4. 2-(4-(3,4-dichlorophenyl)piperazin-1-yl)-N-(5-nitrothiazol-2-yl)acetamide (5): Bright 
yellow microcrystals (65%): mp 169-171 oC; 1H NMR (400 MHz, (CD3COCD3) δ: 8.44 (s, 1H), 7.36 (d, J 
= 9.2 Hz, 1H), 7.12 (d, J = 2.8 Hz, 1H), 6.97 (dd, J = 9.2, 2.8 Hz, 1H), 3.53 (s, 2H), 3.37 (t, J = 5.2 Hz, 
4H), 2.84 (t, J = 5.2 Hz, 4H). HRESIMS calcd for C15H16Cl2N5O3S m/z [M+H]+  416.0345, 418.0317, found 
416.0346, 418.0317. 
 
3.1.3.5. 2-(4-((4-chlorophenyl)(phenyl)methyl)piperazin-1-yl)-N-(5-nitrothiazol-2-yl)acetamide 
(6): Orange microcrystallic powder (66%): mp 92-95 oC; 1H NMR (400 MHz, (CDCl3) δ: 8.31 (s, 1H), 
7.36-7.21 (m, 9H),  4.27 (s, 1H), 3.31 (s, 2H), 2.66 (t, J = 4.8  Hz, 4H ), 2.49 (br s, 4H ). HRESIMS calcd 
for C22H23ClN5O3S m/z [M+H]+ 472.1205, found 472.1209.  
 
3.1.3.6. N-(5-nitrothiazol-2-yl)-2-(4-(pyridin-2-yl)piperazin-1-yl)acetamide (7): Orange 
microcrystallic powder (56%): mp 175-180 oC (dec); 1H NMR (400 MHz, (CDCl3) δ: 8.33 (s, 1H), 8.21 
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(dd, J = 4.4, 1.2 Hz, 1H), 7.52 (dt, J = 8.4, 2.0  Hz, 1H), 6.68 (m, 2H), 3.65 (t, J = 4.8  Hz, 4H ) 3.38 (s, 
2H), 2.76 (t, J = 4.8,  Hz, 4H ). HRESIMS calcd for C14H17N6O3S m/z [M+H]+ 349.1077 found 349.1083. 
 
3.1.4. N-(5-nitrothiazol-2-yl)-[1,1'-biphenyl]-4-carboxamide (8): [1,1'-Biphenyl]-4-carbonyl 
chloride was added in portions to a suspension of 5-nitrothiazol-2-amine (1 eq) and triethylamine (2.5 
eq) in 10-12 mL dichloromethane. The reaction mixture was kept at room temperature overnight 
under stirring and a nitrogen atmosphere. The desired product was obtained after preparative TLC 
on silica gel plates using ethyl acetate : petroleum ether (50:50) as eluent. Beige microcrystals (55%): 
mp > 230 oC ; 1H NMR (400 MHz, (CD3COCD3) δ: 8.50 (s, 1H), 8.31 (d, J = 8.8 Hz, 2H), 7.92 (d, J = 8.8 
Hz, 2H), 7.78 (d, J = 7.6 Hz, 2H), 7.53 (t, J = 7.6 Hz, 2H), 7.45 (t, J = 7.6 Hz, 1H). HRESIMS calcd for 
C16H10N3O3S m/z [M-H]-  324.0448 found 324.0464.  
 
3.1.5. General synthesis of N-(5-nitrothiazol-2-yl)acetamides 9-12: 
An appropriate phenol (1.05 eq) and K2CO3 (2.1 eq) were mixed together in dry DMF (4 mL) and 
stirred for an hour. Then a DMF solution (4 mL) of 2-chloro-N-(5-nitrothiazol-2-yl)acetamide (1 eq) 
was added through a funnel and the reaction mixture was heated at 60 oC for 3-4 h. The solvent was 
evaporated and the residue was chromatographed on silica gel preparative TLC plates using ethyl acetate : 
petroleum ether mixture as an eluent. The desired product is formed in relatively small yield (≤ 35%) and 
appears immediately after the unreacted phenol on TLC. Changing the solvent to CH3CN or DMSO did not 
improve the yield. 
 
3.1.5.1. 2-([1,1'-biphenyl]-3-yloxy)-N-(5-nitrothiazol-2-yl)acetamide (9): White microcrystals 
(25%): mp 148-150 oC; 1H NMR (400 MHz, (CClD3) δ: 9.94 (br s, 1H), 8.36 (s, 1H), 7.60-7.33 (m, 7H), 
7.21 (dd, J = 2.4, 1.6 Hz, 1H), 6.96 (dd, J = 7.2, 2.4, Hz, 1H), 4.85 (s, 2H). HRESIMS calcd for C17H14N3O4S 
m/z [M+H]+ 356.0700, found 356.0696.  
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3.1.5.2. N-(5-nitrothiazol-2-yl)-2-(3-phenoxyphenoxy)acetamide (10): White microcrystals (34 %, 
based on recovered phenol): mp 151-153 oC; 1H NMR (400 MHz, (CDCl3) δ: 9.84 (br s, 1H), 8.35 (s, 1H), 
7.38 (t, J = 7.6 Hz, 2H), 7.30 (t,  J = 8.0 Hz, 1H), 7.17 (t, J = 8.0 Hz, 1H), 7.05 (d, J = 7.6 Hz, 2H), 6.73 
(dd, J = 8.0, 2.0 Hz, 1H), 6.68 (dd, J = 8.0, 2.4 Hz, 1H), 6.62 (t, J = 2.4Hz, 1H), 4.74 (s, 2H).  HRESIMS 
calcd for C17H14N3O5S m/z [M+H]+ 372.0648, found 372.0649.  
 
3.1.5.3. 2-([1,1'-biphenyl]-4-yloxy)-N-(5-nitrothiazol-2-yl)acetamide (11): Light yellow 
microcrystals  (35 %, based on recovered phenol): mp 196-198 oC; 1H NMR (400 MHz, CDCl3) δ: 8.36 (s, 
1H), 7.60 (d, J = 8.8 Hz, 2H), 7.55 (dd, J = 8.0, 0.8 Hz, 2H), 7.44 (t, J = 7.2 Hz, 2H), 7.35 (t, J = 7.6 Hz, 
1H), 7.06 (d, J = 8.8 Hz, 2H), 4.83 (s, 2H). HRESIMS calcd for C17H14N3O4S m/z [M+H]+  356.070, found 
356.0694.  
 
3.1.5.4. N-(5-nitrothiazol-2-yl)-2-(4-phenoxyphenoxy)acetamide (12): Off white microcrystals (30 
%): mp 185-187 oC; 1H NMR (400 MHz, (CDCl3) δ: 9.91 (br s, 1H), 8.36 (s, 1H), 7.33 (t, J = 8.0 Hz, 2H), 
7.10 (t, J = 7.6 Hz, 1H), 7.05-6.95 (m, 6H), 4.77 (s, 2H). HRESIMS calcd for C17H14N3O5S m/z [M+H]+  
372.0649, found 372.0655.  
 
3.2. Biological evaluation.  
3.2.1. In vitro screening: 
In vitro activity against T. cruzi, T. b. rhodesiense, L. donovani and cytotoxicity assessment using 
L6 cells (rat skeletal myoblasts) was determined using a 96-well plate format as previously 
described [38]. Data were analyzed with the graphic program Softmax Pro (Molecular Devices, 
Sunnyvale, CA, USA), which calculated IC50 values by linear regression from the sigmoidal dose 
inhibition curves. 
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3.2.2. In vitro T. brucei brucei antiproliferating assays and susceptibility studies.   
T. brucei brucei bloodstream form parasites were seeded at 1 x 103 mL-1 in 200 µL of growth medium 
containing different concentrations of a nitrothiazole or nifurtimox. Where appropriate, induction of the 
TbNTR was carried out by adding tetracycline (1 µg/mL). After incubation for 3 days at 37 oC, resazurin 
(2.5 µg per well) was added to each well and the plates incubated for a further 8 h. The cell density of each 
culture was determined as described before [26] and the IC50 established. 
 
3.2.3. Enzymatic activity studies with Type I NTRs.  
Recombinant TbNTR was prepared and assayed as previously described [39, 40]. The activity of purified 
his-tagged TbNTR was assessed spectrophotometrically at 340 nm using various nitrothiazole substrates 
(100 µM) and NADH (100 µM) with the enzyme specific activity expressed as nmol NADH oxidized min-
1 mg-1 of enzyme. Benznidazole was used as control substrate. 
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Captions of Figures  
 
Fig. 1. Correlation between antichagasic activity (log IC50 values against T. cruzi) and lipophilicity 
(clogP values) in 3-7, compounds that are active against T. cruzi and bear a piperazine moiety. 
 
Fig. 2. Correlation between antichagasic activity (log IC50 values against T. cruzi) 
and lipophilicity (clogP values) in the subgroup of structurally similar compounds 8-12. 
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Fig. 3. Correlation between log IC50 values against L. donovani and clogP values for compounds 
in Table 1. 
 
Fig. 4. Correlation between log IC50 values in L6 cells and clogP values for compounds in Table 
1. 
 
Fig. 5. Specific activity values are measured in nmol NADH oxidized min-1 mg-1 TbNTR. The 
values correspond to averages from assays performed in triplicate ± standard deviation 
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Highlights: 
• Novel 5-nitro-2-aminothiazole-based amides were synthesized. 
• Compounds were tested for antiparasitic activity and toxicity in L6 cells.  
• Most derivatives were active or moderately active against T. cruzi and T. brucei. 
• Some analogs demonstrated moderate antileishmanial activity in vitro. 
• Lipophilicity positively affects antichagasic and antileishmanial activity. 
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• These compounds are not activated by Type I nitroreductases. 
 
 
 
 
